Chen, Hongli
Wang, Fangxia
Zhang, Pengyu
Zhang, Yilin
Chen, Yinxia
Fan, Xiaohu
Cao, Xingmei
Liu, Jie
Yang, Yun
Wang, Baiyan
Lei, Bo
Gu, Liufang
Bai, Ju
Wei, Lili
Zhang, Ruili
Zhuang, Qiuchuan
Zhang, Wanggang
Zhao, Wanhong
He, Aili
Article History
Received: 19 May 2019
Accepted: 5 August 2019
First Online: 28 September 2019
Compliance with ethics guidelines
: Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, and Aili He declare no competing interests. The clinical trials of LCAR-B38M therapy and CD19-CAR-T cells therapy were approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 <i>Helsinki Declaration</i> and its later amendments or comparable ethical standards.